UroGen Pharma Ltd. (URGN) stock
URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$31.73+1.94 (+6.51%)
Close on Nov 19, 2026Market cap $1.55BP/E –Yield –
UroGen Pharma revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
UroGen Pharma's revenue for the twelve months ending Jun 30, 2026 was $188.73M, up 100.3% year over year. For fiscal 2025 it was $109.79M, up 21.4% from the year before. The highest annual figure on record is $109.79M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $109.79M | +21.4% |
| FY2024 | Dec 31, 2024 | $90.40M | +9.3% |
| FY2023 | Dec 31, 2023 | $82.71M | +28.5% |
| FY2022 | Dec 31, 2022 | $64.36M | +34.0% |
| FY2021 | Dec 31, 2021 | $48.04M | +307.2% |
| FY2020 | Dec 31, 2020 | $11.80M | +65450.0% |
| FY2019 | Dec 31, 2019 | $18.00K | -98.4% |
| FY2018 | Dec 31, 2018 | $1.13M | -86.2% |
| FY2017 | Dec 31, 2017 | $8.16M | -53.5% |
| FY2016 | Dec 31, 2016 | $17.53M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $72.46M | +199.2% |
| Q1 FY2026 | Mar 31, 2026 | $50.96M | +151.6% |
| Q4 FY2025 | Dec 31, 2025 | $37.84M | +54.0% |
| Q3 FY2025 | Sep 30, 2025 | $27.48M | +9.0% |
| Q2 FY2025 | Jun 30, 2025 | $24.22M | +10.8% |
| Q1 FY2025 | Mar 31, 2025 | $20.25M | +7.8% |
| Q4 FY2024 | Dec 31, 2024 | $24.57M | +4.4% |
| Q3 FY2024 | Sep 30, 2024 | $25.20M | +20.9% |
| Q2 FY2024 | Jun 30, 2024 | $21.85M | +3.4% |
| Q1 FY2024 | Mar 31, 2024 | $18.78M | +9.2% |
| Q4 FY2023 | Dec 31, 2023 | $23.53M | +30.1% |
| Q3 FY2023 | Sep 30, 2023 | $20.85M | +29.5% |
| Q2 FY2023 | Jun 30, 2023 | $21.14M | +27.3% |
| Q1 FY2023 | Mar 31, 2023 | $17.19M | +26.7% |
| Q4 FY2022 | Dec 31, 2022 | $18.09M | +11.9% |
| Q3 FY2022 | Sep 30, 2022 | $16.10M | +41.8% |
| Q2 FY2022 | Jun 30, 2022 | $16.60M | +27.4% |
| Q1 FY2022 | Mar 31, 2022 | $13.56M | +81.2% |
| Q4 FY2021 | Dec 31, 2021 | $16.17M | +103.0% |
| Q3 FY2021 | Sep 30, 2021 | $11.35M | +228.0% |
| Q2 FY2021 | Jun 30, 2021 | $13.03M | +3403.2% |
| Q1 FY2021 | Mar 31, 2021 | $7.49M | – |
| Q4 FY2020 | Dec 31, 2020 | $7.97M | – |
| Q3 FY2020 | Sep 30, 2020 | $3.46M | +19127.8% |
| Q2 FY2020 | Jun 30, 2020 | $372.00K | – |
| Q4 FY2019 | Dec 31, 2019 | $0 | -100.0% |
| Q3 FY2019 | Sep 30, 2019 | $0 | -100.0% |
| Q2 FY2019 | Jun 30, 2019 | $18.00K | -96.3% |
| Q4 FY2018 | Dec 31, 2018 | $0 | -100.0% |
| Q3 FY2018 | Sep 30, 2018 | $283.00K | -96.4% |
| Q2 FY2018 | Jun 30, 2018 | $364.00K | – |
| Q1 FY2018 | Mar 31, 2018 | $481.00K | +2431.6% |
| Q4 FY2017 | Dec 31, 2017 | $327.00K | – |
| Q3 FY2017 | Sep 30, 2017 | $7.81M | – |
| Q2 FY2017 | Jun 30, 2017 | $0 | – |
| Q1 FY2017 | Mar 31, 2017 | $19.00K | – |
See a number that looks wrong?